Mono, dual and triple moxifloxacin-based therapies for Helicobacter pylori eradication
S Di Caro, V Ojetti, M A Zocco, F Cremonini, F Bartolozzi, M Candelli, A Lupascu, E C Nista, G Cammarota, A Gasbarrini, S Di Caro, V Ojetti, M A Zocco, F Cremonini, F Bartolozzi, M Candelli, A Lupascu, E C Nista, G Cammarota, A Gasbarrini
Abstract
Background: Moxifloxacin is a broad spectrum fluoroquinolone with single daily administration, currently used, above all, for respiratory tract infections.
Aim: To compare the efficacy of different 1-week moxifloxacin-based Helicobacter pylori eradication regimens.
Methods: One hundred and twenty H. pylori-positive subjects were randomized to receive moxifloxacin (400 mg/day), moxifloxacin (400 mg/day) and lansoprazole (30 mg/day) or moxifloxacin (400 mg/day), lansoprazole (30 mg/day) and clarithromycin (500 mg b.d.). H. pylori status was reassessed 6 weeks after the end of therapy, and both intention-to-treat and per protocol analyses were performed.
Results: One hundred and nineteen of the 120 patients completed the study. H. pylori eradication was achieved in 22.5% of patients treated with moxifloxacin, in 33.3% of subjects treated with moxifloxacin and lansoprazole and in 90% of patients treated with moxifloxacin, clarithromycin and lansoprazole.
Conclusions: Mono and dual moxifloxacin-based therapies are not acceptable for H. pylori eradication; conversely, moxifloxacin-based triple therapy may be considered as a new, effective, first-line therapy option.
Source: PubMed